BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34627448)

  • 1. [The Expression and Significance of Serum Protein ROCK2 in Patients with Chronic Graft-Versus-Host Disease].
    Tang P; Zheng CH; Dong ZK; Xie MH; Xie XS; Sun H; Sun L; Wan DM; Liu YF; Jiang ZX; Guo R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1606-1609. PubMed ID: 34627448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease].
    Chen T; Li XP; Zhang C; Kong PY; Gao QG; Tang L; Wang R; Yang SJ; Gao L; Liu Y; Gao L; Feng YM; Rao J; Peng XG; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):948-952. PubMed ID: 31856446
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
    Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
    [No Abstract]   [Full Text] [Related]  

  • 4. The predictive value of serum free light chain level early after allogeneic hematopoietic stem cell transplantation for chronic graft-versus-host disease, a preliminary study.
    Wang B; Liang Z; Liu W; Sun Y; Cen X; Dong Y; Ren H
    Clin Transplant; 2020 Jul; 34(7):e13865. PubMed ID: 32242991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation between immune reconstitution and chronic graft-versus-host disease after unrelated cord blood transplantation and sibling peripheral blood stem cell transplantation].
    Wang J; Pan TZ; Huang PP; Sun ZM; Zhu HP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):466-473. PubMed ID: 34384152
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical characteristics of polyserositis as main presentation of chronic graft-versus-host rejection disease after allogeneic hematopoietic stem cell transplantation].
    Wang Q; Li Y; Qiu Z; Xu W; Sun Y; Wang L; Wang M; Liu W; Dong Y; Ou J; Wang W; Liang Z; Wang Q; Cen X; Ren H
    Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):394-7. PubMed ID: 25146408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Yang K; Chen Y; Qi H; Ye Y; Fan Z; Huang F; Zhang H; Suo Y; Liu Q; Jin H
    Front Immunol; 2020; 11():1505. PubMed ID: 32849514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
    Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
    Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease.
    Ljubas Kelecic D; Lelas A; Karas I; Desnica L; Vukic T; Sabol I; Vranesic Bender D; Serventi Seiwerth R; Peric Z; Durakovic N; Vitali Cepo D; Vrhovac R; Nemet D; Pavletic S; Pulanic D; Krznaric Z
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2967-2978. PubMed ID: 32507973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Hu Y; Cui Q; Ye Y; Luo Y; Tan Y; Shi J; Huang H
    Hematol Oncol; 2017 Mar; 35(1):118-124. PubMed ID: 26439896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association of the ratio of regulatory and effector T cells with recurrence and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Wang HT; Zhao XY; Zhao XS; Han TT; Lv M; Chang YJ; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):679-84. PubMed ID: 23978019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.
    Zanin-Zhorov A; Blazar BR
    Clin Immunol; 2021 Sep; 230():108823. PubMed ID: 34400321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belumosudil for chronic graft-versus-host disease.
    Taylor B; Cohen J; Tejeda J; Wang TP
    Drugs Today (Barc); 2022 May; 58(5):203-212. PubMed ID: 35535812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.
    Hao B; Gao S; Sang YW; Wang L; Meng XQ; You JY
    J Zhejiang Univ Sci B; 2019 Oct.; 20(10):849-860. PubMed ID: 31489804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease.
    Novitzky-Basso I; Schain F; Batyrbekova N; Webb T; Remberger M; Keating A; Mattsson J
    PLoS One; 2023; 18(3):e0282753. PubMed ID: 36893113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
    Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
    Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.